Trial record 1 of 5 for:    "Epilepsy, Frontal Lobe" OR "autosomal dominant nocturnal frontal lobe epilepsy"
Previous Study | Return to List | Next Study

Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.

This study has been completed.
Sponsor:
Information provided by:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT00382707
First received: September 28, 2006
Last updated: August 29, 2011
Last verified: August 2011
  Purpose

Epileptic disease is characterised by enhanced brain excitability. Low frequency repetitive transcranial magnetic stimulation (rTMS) can be an effective treatment for refractory frontal epilepsy. Thought, physiological mechanisms of its effectivity are still unknown. It is yet possible to evaluate cortical excitability and inhibition with TMS-coupled electromyography before and after rTMS sessions ; this could provide clues for basic mechanisms of rTMS effects on the epileptic brain. We assume that rTMS decrease brain excitability by improving brain inhibition. Such an information could help for treating patients with both pharmacological and non-pharmacological methods.


Condition Intervention
Refractory Frontal Lobe Epilepsy
Device: cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.

Resource links provided by NLM:


Further study details as provided by University Hospital, Strasbourg, France:

Primary Outcome Measures:
  • Electrophysiological parameters for cortical excitability measured just before and after rTMS, 4 hours later and 24 hours later.

Secondary Outcome Measures:
  • Clinical efficacity on seizure intensity and frequency.

Estimated Enrollment: 15
Study Start Date: May 2006
Study Completion Date: August 2011
  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cryptogenic frontal lobe epilepsy
  • Normal cerebral MRI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00382707

Locations
France
Département de Neurologie - Hôpital Civil
Strasbourg, France, 67091
Institut de Physique Biologique
Strasbourg, France, 67091
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Study Director: Serge CHASSAGNON, MD Hôpitaux Universitaires de Strasbourg
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00382707     History of Changes
Other Study ID Numbers: 3540
Study First Received: September 28, 2006
Last Updated: August 29, 2011
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Strasbourg, France:
repetitive transcranial magnetic stimulation
low frequency
frontal lobe epilepsy
brain excitability
electromyography

Additional relevant MeSH terms:
Epilepsy
Epilepsy, Frontal Lobe
Brain Diseases
Central Nervous System Diseases
Epilepsies, Partial
Nervous System Diseases
Anticonvulsants
Central Nervous System Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 21, 2014